AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01115933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE PRIME SV EECSS
Description: Patients receiving XIENCE PRIME SV EECSS
Study NCT04217538 — intervention group
Intervention type: OTHER
Intervention: clinical exam
Description: clinical oral examination
Study NCT01656798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: 2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
Study NCT00481026 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS
Study NCT00481026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Active tDCS
Study NCT02351167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination NRT (Nicotine patch, Nicotine lozenge)
Study NCT02351167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Study NCT02351167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02351167 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive smoking counseling
Study NCT02351167 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive smoking counseling
Study NCT04379284 — intervention group
Intervention type: OTHER
Intervention: Biospecimen collection
Description: Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab.
Study NCT03211351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposic
Description: one eye of the participant recieved Lipoic
Study NCT03211351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: the other eye of the participant recieved Tears Naturale Forte
Study NCT00597428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg capsules twice daily (BID)
Study NCT00597428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg capsules twice daily (BID)
Study NCT03828409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long stitch
Description: Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy
Study NCT01776047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge®
Study NCT02118025 — intervention group
Intervention type: PROCEDURE
Intervention: Off-pump coronary artery bypass graft
Description: Patients operated with the heart beating, without heart arrest.
Study NCT02118025 — intervention group
Intervention type: PROCEDURE
Intervention: Mini extracorporeal circulation bypass
Description: Patients operated with a modified extracorporeal circulation system
Study NCT03837171 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Red blood cell transfusion
Description: Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians
Study NCT03837171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Restrictive Red blood cell transfusion
Description: Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
Study NCT04618939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BR-TD-1001
Description: 0.5 mL, IM
Study NCT04618939 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td-pur inj
Description: 0.5 mL, IM
Study NCT02203578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT02203578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03385954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
Study NCT03385954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: will receive a lecture of 30 minutes.
Study NCT04018690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine
Description: Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis.
Study NCT04018690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,
Description: Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis.
Study NCT01932190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early RRT strategy
Description: the early strategy : RRT is started immediately when a RIFLE F status is documented
Study NCT01932190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed RRT strategy
Description: The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary
Study NCT01263561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ExPRESS shunt
Description: ExPRESS miniature glaucoma drainage device
Study NCT01263561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Description: trabeculectomy filtering surgery
Study NCT03354208 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
Study NCT01897441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02659371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low energy diet
Study NCT01897441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT01776047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-0081
Study NCT02645721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended self-help program with guidance
Description: See arm description for Experimental
Study NCT02645721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Briefer Self-help program, no guidance
Description: See arm description for Active Comparator
Study NCT02645721 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WL: Extended self-help program, choice of guidance intensity
Description: See arm description for Waiting list.
Study NCT03031158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFEX+H
Description: Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
Study NCT03031158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SFEX
Description: Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
Study NCT02565459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Study NCT03783975 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Simplified Cascade Screening
Description: Screening of the KCNQ1 Thr224Met variant for family members of probands
Study NCT03130491 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Description: placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
Study NCT03130491 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EMBLOK filter
Description: Embolic Filter Protection System During TAVR
Study NCT04738409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA\&T), in terms of improvement in androgens level and immune-metabolic risk parameters
Study NCT04738409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls
Description: The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
Study NCT00487682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: oral
Study NCT02498613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-Fluoromisonidazole
Description: Correlative studies
Study NCT00487682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir hydrochloride
Description: oral
Study NCT03316339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Opioid-free anesthesia
Study NCT02498613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT03316339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Opioid anesthesia
Study NCT04609969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-qPCR test
Description: Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
Study NCT04609969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-VIRO® test
Description: Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
Study NCT04336410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.
Study NCT04336410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
Study NCT02498613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03181984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoporfin
Description: Hemoporfin mediated photodynamic therapy
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
Study NCT03756961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC)
Description: The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
Study NCT01501396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
Study NCT03756961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulation (TENS)
Description: The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
Study NCT03756961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
Study NCT01501396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Study NCT02714907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortrium C3 device
Description: Data is read from Cortrium C3 monitor
Study NCT02714907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter device
Description: Date is read from Holter device
Study NCT03339687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Mindset Induction
Description: This induction of a psychological state was extensively studied in cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps.
Study NCT01986907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
Study NCT00810693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
Study NCT00810693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521: 1.5mg tid orally for 12 weeks
Study NCT00810693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tid orally for 12 weeks
Study NCT01209923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BC1
Description: Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
Study NCT02409212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
Study NCT02409212 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo surveillance and written exercise guidelines
Description: Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
Study NCT02069132 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
Study NCT03835910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentives and Gamification to Promote Exercise
Description: The intervention will provide social incentives and gamification to promote physical activity.
Study NCT03835910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection given in A-B order
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
Study NCT03835910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection given in A-B order
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
Study NCT03835910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Social Incentive applied
Description: No social incentive will be applied
Study NCT03835910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection given in B-A order
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
Study NCT03835910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection given in B-A order
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
Study NCT01626495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.